Recent News

• 05.28.2025 - MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
• 05.08.2025 - MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review
• 05.06.2025 - MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity
• 04.23.2025 - MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
• 04.16.2025 - MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
• 04.01.2025 - MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
• 03.24.2025 - MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Recent Filings

• 05.28.2025 - 8-K Current report
• 05.21.2025 - 8-K Current report
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - 8-K Current report
• 05.06.2025 - 8-K Current report
• 04.23.2025 - 8-K Current report
• 04.17.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.16.2025 - 8-K Current report
• 04.15.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]